CD274 and cancer: Clinical trials for anti-PD-1/PD-L1 have been conducted to treat various other cancers, such as lung adenocarcinoma18,21, mismatch-repair-deficient colorectal carcinoma18,22, renal cell carcinoma18,23, and bladder cancer.24